MENU
jpma
  • Access
  • Japanese
  • Global Health

    Global Health TOP

    • Sustainable Development Goals, SDGs
    • Universal Health Coverage
    • Value and Access of medicines
    • Intellectual Property (IP)
    • Infectious Diseases
    • Non-Communicable Diseases (NCDs)
    • Countermeasures against Counterfeit Medicines
    • Global Health Issues
    • JPMA Position Statements
    • JPMA Global Health Events
  • Activities

    Activities TOP

    • International Affairs Committee(Asia Committee)
    • Pharmaceutical Industrial Policy Committee
    • Deliverables of Drug Evaluation Committee
    • Quality & Technology Committee
    • R & D Committee
    • Others
  • Code

    Code TOP

    • JPMA Industry Vision 2025
    • JPMA Charter of Corporate Behavior
    • Code of Practice
    • Transparency Guideline
    • Intellectual Property
    • Global Health
  • About Us

    About Us TOP

    • About JPMA
    • President's Message
    • Officers
    • Structure of JPMA
    • Related Organizations
    • Member Companies
    • Video
    • Access
    • JPMA Industry Vision 2025
    • Pharmaceutical Regulations in Japan
  • ICH Project

    ICH Project TOP

    • ICH Public Meetings
    • ICH-branded regional meetings
    • Implementation Training Workshop
    • ICH Guideline/Implementation Guide related materials (Translation into English/Japanese)
  • News Room

    News Room TOP

    • News Release
    • Information
Close

Site TOP

  • Global Health
    Global Health TOP
    • Sustainable Development Goals, SDGs
    • Universal Health Coverage
    • Value and Access of medicines
    • Intellectual Property (IP)
    • Infectious Diseases
    • Non-Communicable Diseases (NCDs)
    • Countermeasures against Counterfeit Medicines
    • Global Health Issues
    • JPMA Position Statements
    • JPMA Global Health Events
  • Code
    Code TOP
    • JPMA Industry Vision 2025
    • JPMA Charter of Corporate Behavior
    • Code of Practice
    • Transparency Guideline
    • Intellectual Property
    • Global Health
  • About Us
    About Us TOP
    • About JPMA
    • President's Message
    • Officers
    • Structure of JPMA
    • Related Organizations
    • Member Companies
    • Video
    • Access
    • JPMA Industry Vision 2025
    • Pharmaceutical Regulations in Japan
  • ICH Project
    ICH Project TOP
    • ICH Public Meetings
    • ICH-branded regional meetings
    • Implementation Training Workshop
    • ICH Guideline/Implementation Guide related materials (Translation into English/Japanese)
  • News Room
    News Room TOP
    • News Release
    • Information
  • Asia Partnership Conference of Pharmaceutical Associations(APAC)
  • Access
  • Japanese
  • Home
  • Activities
  • Deliverables of Drug Evaluation Committee

JPMA Committee Activities Deliverables of Drug Evaluation Committee

  • all
  • Expert Committees
  • CTD Structure Using the Results of Multi-Regional Clinical Trials Based on the Principles in ICH E17 (2023,12)
  • Drug Evaluation From Now On --- What's the value of local data in the global clinical data package? (2022,12)
  • Implementation and Management, etc. of Clinical trials under the spread of the novel coronavirus (COVID-19) (2020,04)
  • Commonly used analysis shells and ADaM data for clinical study reports (2019,12)
  • For Sharing Individual Participant/Patient Data (IPD) from Clinical Trials (2019,10)
  • Consensus Statement on MA/MSL activities (2019,04)

share

  • Tweet
  • share

TOP

Search

  • Home
  • Activities
  • Deliverables of Drug Evaluation Committee
  • Global Health
  • JPMA Committee Activities
  • Code
  • About Us
  • ICH
  • OPIROpen link in new window.
  • X
  • facebook
  • youtube
  • Sitemap
  • Link

© Japan Pharmaceutical Manufacturers
Association(JPMA).All rights reserved.